Literature DB >> 22280405

Targeting vascular changes in lesions in multiple sclerosis and experimental autoimmune encephalomyelitis.

Stephen J Karlik1, Wendi A Roscoe, Cindy Patinote, Christiane Contino-Pepin.   

Abstract

What is the origin of the complex vascular changes that exist in the CNS lesions of Multiple Sclerosis (MS)? From the beginning of the study of the pathological changes in MS in the 19th century, lesions were seen to be associated with veins. On a microscopic level, there have been numerous pathological changes to these vessels including altered structure and permeability, fibrinolysis, iron-related alterations and collagen deposition. Vascular changes in inflammatory conditions outside the CNS are well documented and we hypothesize that angiogenesis (the generation of new blood vessels from existing) is an integral process of lesion development and spread in MS. We demonstrated similar vascular abnormalities in MS and in the animal model, EAE. We measured the increase in angiogenesis-related genes in EAE and review herein the effectiveness of chemical inhibitors of angiogenesis (SU5416, thalidomide and several derivatives). We postulate that interference with angiogenesis provides a suitable non-immunological target for investigation in MS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22280405     DOI: 10.2174/187152412800229125

Source DB:  PubMed          Journal:  Cent Nerv Syst Agents Med Chem        ISSN: 1871-5249


  5 in total

1.  A Peptide Targeting Inflammatory CNS Lesions in the EAE Rat Model of Multiple Sclerosis.

Authors:  Claudine Boiziau; Macha Nikolski; Elodie Mordelet; Justine Aussudre; Karina Vargas-Sanchez; Klaus G Petry
Journal:  Inflammation       Date:  2018-06       Impact factor: 4.092

2.  Inhibition of angiogenesis by β-galactosylceramidase deficiency in globoid cell leukodystrophy.

Authors:  Mirella Belleri; Roberto Ronca; Daniela Coltrini; Beatrice Nico; Domenico Ribatti; Pietro L Poliani; Arianna Giacomini; Patrizia Alessi; Sergio Marchesini; Marta B Santos; Ernesto R Bongarzone; Marco Presta
Journal:  Brain       Date:  2013-09       Impact factor: 13.501

3.  Screening for Interacting Proteins with Peptide Biomarker of Blood-Brain Barrier Alteration under Inflammatory Conditions.

Authors:  Karina Vargas-Sanchez; Monica Losada-Barragán; Maria Mogilevskaya; Susana Novoa-Herrán; Yehidi Medina; Cristian Buendía-Atencio; Vaneza Lorett-Velásquez; Jessica Martínez-Bernal; Rodrigo E Gonzalez-Reyes; David Ramírez; Klaus G Petry
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

Review 4.  Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Francesco Girolamo; Cristiana Coppola; Domenico Ribatti; Maria Trojano
Journal:  Acta Neuropathol Commun       Date:  2014-07-22       Impact factor: 7.801

Review 5.  Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders.

Authors:  Yoo Jin Jung; David Tweedie; Michael T Scerba; Dong Seok Kim; Maria Francesca Palmas; Augusta Pisanu; Anna R Carta; Nigel H Greig
Journal:  Front Neurosci       Date:  2021-03-29       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.